Dietary Supplementation for Retinitis Pigmentosa: A Report by the American Academy of Ophthalmology.

IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Ophthalmology Pub Date : 2024-10-23 DOI:10.1016/j.ophtha.2024.09.004
Nieraj Jain, Maureen G Maguire, Christina J Flaxel, Stephen J Kim, Shriji Patel, Justine R Smith, Christina Y Weng, Leo A Kim, Steven Yeh
{"title":"Dietary Supplementation for Retinitis Pigmentosa: A Report by the American Academy of Ophthalmology.","authors":"Nieraj Jain, Maureen G Maguire, Christina J Flaxel, Stephen J Kim, Shriji Patel, Justine R Smith, Christina Y Weng, Leo A Kim, Steven Yeh","doi":"10.1016/j.ophtha.2024.09.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To review the evidence on the effectiveness of dietary supplementation for retinitis pigmentosa (RP).</p><p><strong>Methods: </strong>A literature search of the PubMed database was last conducted in January 2024 to identify published English-language original research on dietary supplementation for RP. Eligible compounds included products ingested orally containing nutrients intended to supplement the diet. Studies meeting eligibility criteria were assigned a level of evidence rating by the panel methodologist.</p><p><strong>Results: </strong>The search identified 283 citations, 15 of which met the assessment criteria. Two studies were rated level I, 11 studies were rated level II, and 2 studies were rated level III. All were single-center studies and were published between 1993 and 2022. The products evaluated included vitamin A, docosahexaenoic acid (DHA), lutein, vitamin E, goji berry (Lycium barbarum fruit) extract, and chlorogenic acid. Primary outcome measures were most commonly based on electroretinography (n = 7) or perimetry (n = 2) testing. Numerous studies highlighted data suggestive of possible efficacy for vitamin A, DHA, and lutein, yet these findings typically derived from secondary outcomes, evaluations of participant subsets, post hoc analyses, problematic interpretations of the data, or a combination thereof. Additionally, it was often unclear if the study findings represented clinically meaningful outcomes. No prominent safety concerns were reported in any study.</p><p><strong>Conclusions: </strong>No high-quality evidence was found to support the effectiveness of any form of dietary supplementation for RP. The findings underscore the challenges of studying this rare and slowly progressive retinal disease. Future studies should leverage the enhanced recruitment abilities from collaborative research networks to refine eligibility criteria while using novel, clinically meaningful endpoints.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":13.1000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ophtha.2024.09.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To review the evidence on the effectiveness of dietary supplementation for retinitis pigmentosa (RP).

Methods: A literature search of the PubMed database was last conducted in January 2024 to identify published English-language original research on dietary supplementation for RP. Eligible compounds included products ingested orally containing nutrients intended to supplement the diet. Studies meeting eligibility criteria were assigned a level of evidence rating by the panel methodologist.

Results: The search identified 283 citations, 15 of which met the assessment criteria. Two studies were rated level I, 11 studies were rated level II, and 2 studies were rated level III. All were single-center studies and were published between 1993 and 2022. The products evaluated included vitamin A, docosahexaenoic acid (DHA), lutein, vitamin E, goji berry (Lycium barbarum fruit) extract, and chlorogenic acid. Primary outcome measures were most commonly based on electroretinography (n = 7) or perimetry (n = 2) testing. Numerous studies highlighted data suggestive of possible efficacy for vitamin A, DHA, and lutein, yet these findings typically derived from secondary outcomes, evaluations of participant subsets, post hoc analyses, problematic interpretations of the data, or a combination thereof. Additionally, it was often unclear if the study findings represented clinically meaningful outcomes. No prominent safety concerns were reported in any study.

Conclusions: No high-quality evidence was found to support the effectiveness of any form of dietary supplementation for RP. The findings underscore the challenges of studying this rare and slowly progressive retinal disease. Future studies should leverage the enhanced recruitment abilities from collaborative research networks to refine eligibility criteria while using novel, clinically meaningful endpoints.

Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
视网膜色素变性的膳食补充剂:美国眼科学会报告。
目的:回顾膳食补充剂对视网膜色素变性(RP)有效性的证据:最后一次对PubMed数据库进行文献检索是在2024年1月,目的是确定已发表的有关视网膜色素变性膳食补充剂的英语原创研究。符合条件的化合物包括口服产品,其中含有旨在补充饮食的营养物质。符合资格标准的研究由专家组方法论专家进行证据等级评定:检索发现了 283 篇引文,其中 15 篇符合评估标准。2 项研究被评为 I 级,11 项研究被评为 II 级,2 项研究被评为 III 级。所有研究均为单中心研究,发表于 1993 年至 2022 年之间。接受评估的产品包括维生素 A、二十二碳六烯酸 (DHA)、叶黄素、维生素 E、枸杞子提取物和绿原酸。主要结果测量通常基于视网膜电图(7 项)或视周计(2 项)测试。许多研究强调了表明维生素 A、DHA 和叶黄素可能具有疗效的数据,但这些研究结果通常来自次要结果、对参与者子集的评估、事后分析、对数据的错误解释或上述因素的综合。此外,研究结果是否代表有临床意义的结果也往往不明确。所有研究均未报告突出的安全性问题:没有发现高质量的证据支持任何形式的膳食补充剂对 RP 有效。研究结果凸显了研究这种罕见且缓慢进展的视网膜疾病所面临的挑战。未来的研究应利用合作研究网络增强的招募能力来完善资格标准,同时采用新颖的、有临床意义的终点:专利或商业信息披露见本文末尾的 "脚注和披露"。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ophthalmology
Ophthalmology 医学-眼科学
CiteScore
22.30
自引率
3.60%
发文量
412
审稿时长
18 days
期刊介绍: The journal Ophthalmology, from the American Academy of Ophthalmology, contributes to society by publishing research in clinical and basic science related to vision.It upholds excellence through unbiased peer-review, fostering innovation, promoting discovery, and encouraging lifelong learning.
期刊最新文献
Corrigendum. Special Commentary: Cerebral/Cortical Visual Impairment Working Definition: A Report from the National Institutes of Health CVI Workshop. What Is Cerebral/Cortical Visual Impairment and Why Do We Need a New Definition? Cavernous Hemangioma of the Retina and Brain. A Child with Posterior Ectopic Cilia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1